Due to the implication of MDM2 in cancer regulation, there is a great interest in the development of selective inhibitors that impair the binding of the E3 ligase to the oncosuppressor protein p53 favoring cell death [133,134,135,136,137,138]. This evidence concerns the gene TP53 and cancer.